Comparing biologic options for the management of Behcet's disease-related uveitis. (4th March 2023)

• Record Type: Journal Article
• Authors: Vitale, Antonio; Caggiano, Valeria; Berlengiero, Virginia; Perfetti, Maria Orsetta; Sota, Jurgen; Tosi, Gian Marco; Frediani, Bruno; Cantarini, Luca; Fabiani, Claudia
• Is Part Of: Expert review of clinical immunology. Volume 19:Number 3(2023)
• Page Start: 315
• Page End: 328
• Publication Date: 2023-03-04
• Subjects: Anakinra -- canakinumab -- eyes -- IL-17 -- ocular inflammation -- personalised therapy -- rituximab -- TNF -- tumor necrosis factor -- tocilizumab; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2023.2174103
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Introduction: Behçet's disease (BD) associated uveitis occurs in approximately 50–70% of the patients. Ocular involvement in BD may induce a severe affection of visual function, leading to a considerable decrease in patients' quality of life. The risk for severe visual loss increases when the ocular posterior segment is involved and in patients with no adequate treatment. Areas covered: Monoclonal tumor necrosis factor (TNF) biotechnological inhibitors represent a relatively recent milestone for the treatment of non-infectious uveitis (NIU) also in BD patients. In addition to TNF inhibitors, further biologic agents have been increasingly proposed for multi-recalcitrant cases, as for interleukin (IL)-1 and IL-6 inhibitors. However, evidence on these new opportunities requires to be widened in the next future. Expert opinion: Joining the forces for scientific efforts is essential to quickly obtain solid acquisitions useful for the everyday clinical practice. To this end, the Auto-Inflammatory Disease Alliance (AIDA) Network has recently supported the development of an international registry dedicated to NIU and other inflammatory ocular involvement observed in BD patients. This will be essential to resolve current and future unmet needs burdening the everyday clinical practice.